Product Information for the Patient

Trabectedina Stada 0.25 mg Powder for Concentrate for Solution for Infusion EFG

Trabectedina Stada 1 mg Powder for Concentrate for Solution for Infusion EFG

Read this entire product information carefully before starting to use this medication, as it contains important information for you.

• Keep this product information, as you may need to refer to it again.
• If you have any questions, consult your doctor.
• If you experience any adverse effects, consult your doctor, even if they are not listed in this product information. See section 4.

This medication has trabectedina as its active ingredient. Trabectedina is an anticancer medication that works by preventing the multiplication of tumor cells.

Trabectedina is used to treat patients with advanced soft tissue sarcoma, when previous treatment with other medications has not been effective or when patients cannot use other medications. Soft tissue sarcoma is a malignant neoplasm that begins in some soft tissues, such as muscles, fat, or other tissues (for example, cartilage or blood vessels).

Trabectedina in combination with pegylated liposomal doxorubicina (DLP, another antitumoral medication) is used to treat patients with ovarian cancer who have experienced a recurrence after at least 1 previous treatment and who are not resistant to anticancer medications containing platinum compounds.

No use Trabectedina Stada

Warnings and Precautions

Consult your doctor before starting to use this medication.

Do not use trabectedina or its combination with DLP if you have severe liver, kidney, or heart problems.

Consult your doctor before starting treatment with trabectedina if you know or suspect that you have:

• liver or kidney problems.
• heart problems or a history of heart problems.
• a left ventricular ejection fraction (LVEF) below the lower limit of normal.
• received high doses of anthracycline in the past.

Seek medical attention immediately if any of the following occur:

• if you have a fever, as trabectedina may cause side effects that affect the blood and liver.

• if, despite taking anti-vomiting medications, you experience nausea, vomiting, or are unable to drink liquids and, therefore, urinate less, seek medical attention immediately.

• if you experience intense muscle pain or weakness, as this could be a sign of muscle damage (rhabdomyolysis, see section 4).

• if you notice that the trabectedina infusion is leaking out of the vein during administration. This could damage or destroy the cells of the surrounding tissues (tissue necrosis; see also section 4), which may require surgical intervention.

• if you experience an allergic reaction (hypersensitivity). In this case, you may experience one or more of the following symptoms: fever, difficulty breathing, redness or flushing of the skin, or rash, dizziness, or nausea, see section 4).

• if you notice general or partial swelling without apparent cause (edema), possibly accompanied by dizziness, vertigo, or thirst (low blood pressure). This could be a manifestation of a disorder (capillary leak syndrome) that may cause an excessive accumulation of fluid in your tissues, and requires urgent clinical evaluation by your doctor.

Children and Adolescents

Trabectedina should not be used in children under 18 years of age with pediatric sarcomas.

Other Medications and Trabectedina Stada

Inform your doctor if you are using, have used recently, or may need to use any other medication.

Do not use trabectedina if you are to be vaccinated against yellow fever and do not recommend its use if you are to be administered a vaccine containing live virus particles. Do not recommend the use of medications containing phenytoin (for epilepsy treatment) with trabectedina, as the effect of phenytoin may be reduced.

If you use any of the following medications during your treatment with trabectedina, you need to be closely monitored, as the effects of trabectedina are:

• reduced (e.g., using medications containing rifampicin (for bacterial infections), phenobarbital (for epilepsy), or St. John's Wort (Hypericum perforatum, a medicinal plant used for depression treatment)) or

• increased (e.g., medications containing ketoconazole or fluconazole (for fungal infections), ritonavir (for HIV infection), clarithromycin (for bacterial infections), aprepitant (to prevent nausea and vomiting), cyclosporine (inhibit the body's defense system), or verapamil (for hypertension and other heart conditions)).

The use of trabectedina with any of these medications should be avoided if possible.

If, in addition to trabectedina or the combination of trabectedina and DLP, you are being administered another medication capable of causing liver or muscle damage (rhabdomyolysis), you may be closely monitored, as this could increase the risk of liver or muscle damage. Medications containing statins (to reduce cholesterol levels and prevent cardiovascular diseases) are an example of medications that can cause muscle damage.

Use of Trabectedina Stada with Alcohol

Alcohol consumption should be avoided during treatment with trabectedina, as it may damage the liver.

Pregnancy, Breastfeeding, and Fertility

Pregnancy

Trabectedina should not be used during pregnancy. If you are pregnant, think you may be pregnant, or intend to become pregnant, consult your doctor before using this medication.

Women of childbearing age should use effective contraceptive methods during treatment with trabectedina and for 3 months after treatment is completed.

If you become pregnant, inform your doctor immediately; in addition, it is recommended that you receive genetic counseling, as trabectedina may cause genetic damage to the fetus.

Breastfeeding

Trabectedina should not be administered to patients who are breastfeeding. Therefore, before starting treatment, you should discontinue breastfeeding and not resume it until your doctor confirms that it is safe to do so.

Fertility

Males of childbearing age should use effective contraceptive methods during treatment with trabectedina and for 5 months after treatment is completed.

Due to the risk of irreversible infertility, it is recommended that patients seek advice on the possibility of preserving their eggs or sperm before treatment.

Genetic counseling is also recommended for patients who wish to have children after treatment.

Driving and Operating Machines

You may feel tired and experience a loss of strength during treatment with trabectedina. Do not drive or operate tools or machines if you experience any of these side effects.

Trabectedina Stada contains sodium

This medication contains less than 23 mg of sodium (1 mmol) per vial; that is, it is essentially "sodium-free".

Trabectedina must be administered under the supervision of a doctor with experience in the use of chemotherapy. Its use should be limited to qualified oncologists and other specialized healthcare professionals in the administration of cytotoxic drugs.

The usual dose for the treatment of soft tissue sarcoma is 1.5 mg/m2of body surface area. During the treatment period, your doctor will closely monitor you and decide on the most suitable dose of trabectedina for you. The recommended dose in Japanese patients is lower than the usual dose for other races and is 1.2 mg/m2of body surface area.

The usual dose for the treatment of ovarian cancer is 1.1 mg/m2of body surface area after administration of 30 mg/m2of body surface area of DLP.

Before administration, trabectedina must be reconstituted and diluted for intravenous use. Each time you are administered trabectedina for the treatment of soft tissue sarcoma, you will need approximately 24 hours for the entire solution to pass into your blood. The treatment of ovarian cancer will last 3 hours.

To avoid irritation in the injection area, it is recommended that you be administered trabectedina through a central venous line.

To protect the liver and reduce the risk of adverse effects such as discomfort (nausea) and vomiting, you will be given other medications before treatment with trabectedina and as needed during treatment.

You will receive an infusion every 3 weeks, although occasionally your doctor may recommend delaying the dose so that you receive the most suitable dose of trabectedina.

The total duration of treatment will depend on your progress and how you feel. Your doctor will tell you how long your treatment may last. If you have any other questions about the use of this medication, ask your doctor.

Like all medicines, this medicine or its combination with DLP may cause side effects, although not everyone will experience them.

If you are unsure about what the following list of side effects are, ask your doctor to explain them in more detail.

Severe side effects caused by treatment with trabectedin:

Very common: may affect more than 1 in 10 people

• You may experience elevated levels of the yellow pigment bilirubin in the blood, which could cause jaundice (yellow pigmentation of the skin, mucous membranes, and eyes).

• Your doctor will ask you to have regular blood tests to detect any abnormalities in the blood.

Common: may affect up to 1 in 10 people

• You may develop blood infections (septicemia) if your immune system is severely affected.If you notice fever, go to your doctor immediately.

• You may also experience muscle pain (myalgia). You may also suffer nerve damage, which causes muscle pain, weakness, and numbness. You may experience general swelling or swelling of the extremities and a sensation of tingling in the skin.

• You may experience a reaction at the injection site. The infusion of trabectedin may leak out of the vein during administration and cause tissue damage and destruction in the surrounding tissues (tissue necrosis; see also section 2 "Warnings and precautions"), which may require surgical intervention.

• You may experience an allergic reaction. In this case, you may have fever, difficulty breathing, redness or flushing of the skin or rash, general discomfort (nausea) or a feeling of discomfort (vomiting).

• When trabectedin is used with DLP, you may experience syncope or fainting. Additionally, you may notice that your heart beats too fast or too hard (palpitations), experience weakness in the ventricles, which are the main pumping chambers of the heart (left ventricular dysfunction), or a sudden blockage of a pulmonary artery (pulmonary embolism).

Uncommon: may affect up to 1 in 100 people

• You may experience intense muscle pain and pain, stiffness, and muscle weakness. You may also experience a darkening of the urine color. All of the above may be a sign of muscle damage (rhabdomyolysis).

• Your doctor may request blood tests in certain situations to prevent muscle damage (rhabdomyolysis). In some very severe cases, this muscle damage may lead to kidney failure.If you experience intense muscle pain or weakness, go to your doctor immediately.

• You may experience difficulty breathing, irregular heart rhythm, decreased urine output, sudden changes in mental state, skin mottling, very low blood pressure associated with abnormal laboratory results (decreased platelet count). If you experience any of these symptoms or signs,go to your doctor immediately.

• You may develop abnormal fluid accumulation in the lungs, which causes swelling (pulmonary edema).

• You may experience general or partial swelling without apparent cause (edema), possibly accompanied by dizziness, vertigo, or thirst (low blood pressure). This may be a manifestation of a disorder (capillary leak syndrome) that can cause excessive fluid accumulation in your tissues. If this happens,go to your doctor immediately.

• The infusion of trabectedin may leak out of your vein while it is being administered (extravasation). Therefore, you may notice redness, swelling, itching, and discomfort in the injection area. If you experience any of these symptoms or signs,inform your doctor or nurse immediately.

This may lead to tissue damage and cell death around the injection site (tissue necrosis), which may require surgery.

Some of the symptoms or signs of extravasation may not be visible until several hours after it occurs. In the area, blisters, peeling, and darkening of the skin may appear. Before the extent of tissue damage becomes visible, it may take several days. If you experience any of these symptoms or signs,go to your doctor immediately.

Rare: may affect up to 1 in 1,000 people

• You may experience yellow discoloration of the skin and eyeball (jaundice), pain in the upper right abdomen, nausea, vomiting, general feeling of discomfort, difficulty concentrating, disorientation or confusion, drowsiness. These signs may be indicative of the liver's inability to perform its normal function. If you experience any of these symptoms or signs,go to your doctor immediately.

Other less severe side effects:

Very common: may affect more than 1 in 10 people

• You may:
• • feel tired
  • experience difficulty breathing and coughing
  • notice back pain
  • have excess fluid in the body (edema)
  • develop bruises (hematomas) more easily
  • experience nasal bleeding
  • be more prone to infections. An infection may also cause fever
  • (fever).

If you experience any of these symptoms, go to your doctor immediately.

• You may also experience some digestive symptoms such as decreased appetite, nausea, vomiting, abdominal pain, diarrhea, or constipation.If you experience nausea despite taking anti-nausea medication, vomit, or are unable to drink liquids and, therefore, urinate less, go to your doctor immediately.

• You may experience headaches.

• You may experience mucosal inflammation, which presents as redness and swelling of the inside of the mouth that causes painful ulcers and sores (stomatitis), or as inflammation of the gastrointestinal tract, when trabectedin is used with DLP.

• Patients receiving trabectedin with DLP for ovarian cancer may also experience hand-foot syndrome. It presents as redness of the skin of the palms of the hands, fingers, and soles of the feet, which, over time, may swell and turn purple. Lesions may be dry and peeling or in the form of blisters with ulceration.

Common: may affect up to 1 in 10 people

• You may experience fluid loss, weight loss, digestive discomfort, and altered sense of taste.

• You may lose hair (alopecia).

• You may experience dizziness, low blood pressure, and hot flashes or skin rash.

• You may notice increased skin pigmentation in patients receiving trabectedin with DLP for ovarian cancer.

• You may experience joint pain.

• You may experience sleep disturbances.

Reporting side effects

If you experience any type of side effect, consult your doctor, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the packaging and on the vial label after CAD. The expiration date is the last day of the month indicated.

Store in refrigerator (2 °C - 8 °C).

Information on stability during use of reconstituted and diluted solutions is included in the section for healthcare professionals.

Do not use this medication if you observe visible particles after reconstitution or dilution of the medication.

Disposal of unused medication and all materials that have been in contact with it will be carried out in accordance with local regulations for cytotoxic medications.

Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of packaging and medications that you no longer need. This will help protect the environment.

Composition of Trabectedina Stada

Trabectedina 0.25 mg: each vial of powder contains 0.25 mg of trabectedina

Trabectedina 1 mg: each vial of powder contains 1 mg of trabectedina.

Appearance of the product and contents of the package

Trabectedina Stada is a powder for concentrate for solution for infusion. The powder has a white to off-white color and is presented in a glass vial.

Each package contains 1 vial of 0.25 mg or 1 vial of 1 mg of trabectedina.

Holder of the marketing authorization and responsible for manufacturing

Holder of the marketing authorization

Laboratorio STADA, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern (Barcelona)

Spain

[email protected]

Responsible for manufacturing

Prestige Promotion Verkaufsförderung und Werbeservice GmbH

Borsigstrasse 2

63755 Alzenau

Germany

or

STADA Arzneimittel GmbH

Muthgasse 36/2

1190 Wien

Austria

or

STADA Arzneimittel AG

Stadastrasse 2 - 18

61118 Bad Vilbel

Germany

or

Laboratori Fundació Dau

Calle Lletra C de la Zona Franca 12-14,

Polígono Industrial de la Zona Franca de Barcelona

08040 Barcelona

Spain

This medicinal product is authorized in the Member States of the European Economic Area with the following names:

Last review date of this leaflet:April 2024

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).

This information is intended solely for healthcare professionals:

Instructions for use, preparation, handling, and disposal

Proper procedures should be followed for the adequate handling and disposal of cytotoxic drugs. The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations for cytotoxic drugs.

The healthcare professional must have received training in the correct techniques for reconstituting and diluting trabectedina or its combination with DLP, and during the reconstitution and dilution of the drug, they must wear protective clothing, including a mask, protective glasses, and gloves. Accidental contact with the skin, eyes, or mucous membranes should be treated immediately with abundant water. If you are pregnant, you should not work with this medication.

Preparation for intravenous infusion

Trabectedina must be reconstituted and then diluted before infusion (see also section 3).

Adequate aseptic techniques should be used.

Trabectedina should not be administered mixed with other medications that are not the diluent, in the same infusion. No incompatibilities have been observed between trabectedina and type I glass vials, or with PVC (polyvinyl chloride) and PE (polyethylene) bags and tubes, or with polyisoprene reservoirs or implantable vascular access systems made of titanium.

When trabectedina is used in combination with DLP, the intravenous route should be thoroughly washed with 50 mg/ml (5%) glucose solution for infusion after administration of DLP and before administration of trabectedina. The use of any diluent other than 50 mg/ml (5%) glucose solution for infusion may cause precipitation of DLP. (See also the summary of characteristics of DLP, which contains specific instructions for its handling).

Instructions for reconstitution

Trabectedina 0.25 mg:inject 5 ml of sterile water for injection into the vial.

Trabectedina 1 mg:inject 20 ml of sterile water for injection into the vial.

A syringe should be used to inject the correct amount of sterile water for injection into the vial. Shake the vial until the drug is completely dissolved. The reconstituted solution is transparent, colorless, or slightly yellowish, without visible particles.

The reconstituted solution has a concentration of 0.05 mg/ml of trabectedina. It requires further dilution and is intended for single use.

Instructions for dilution

Dilutethe reconstituted solution with a 9 mg/ml (0.9%) sodium chloride solution for infusion or a 50 mg/ml (5%) glucose solution for infusion. Calculate the required volume as follows:

SC = body surface area

Extract the appropriate amount of reconstituted solution from the vial; if intravenous administration is to be performed through a central venous route, add the reconstituted solution to a infusion bag containing ≥ 50 ml of diluent (9 mg/ml (0.9%) sodium chloride solution for infusion or 50 mg/ml (5%) glucose solution for infusion), with a trabectedina concentration in the infusion solution ≤ 0.030 mg/ml.

If it is not possible to use a central venous route and a peripheral venous route must be used, the reconstituted solution should be added to an infusion bag containing ≥ 1,000 ml of diluent (9 mg/ml (0.9%) sodium chloride solution for infusion or 50 mg/ml (5%) glucose solution for infusion).

Before intravenous administration, a visual inspection of the parenteral solutions should be performed to detect the possible presence of particles. Once the infusion is prepared, it should be administered immediately.

Stability of solutions during use

Reconstituted solution

After reconstitution, chemical and physical stability has been demonstrated for 30 hours at 25 °C or for up to 21 days if stored between 2 °C and 8 °C.

From a microbiological point of view, the reconstituted solution should be diluted and used immediately. If it is not diluted and used immediately, the storage times in use and conditions before use of the reconstituted solution will be the responsibility of the user, and should normally not exceed 24 hours at 2 °C - 8 °C, unless the reconstitution was performed in validated and controlled aseptic conditions.

Diluted solution

After dilution, chemical and physical stability has been demonstrated for 30 hours at 25 °C.